Tuesday, 02 January 2024 12:17 GMT
عربي


               US          Europe          Arab          Asia          Africa    
|      Politics          Economy     Oil&Energy         
                 Entertainment          Sport

AI-Driven Bioengineering Platforms Revolutionize Protein, Strain, And Drug Design With Multi-Billion Dollar Government Support


2026-02-09 05:31:08
(MENAFN- GlobeNewsWire - Nasdaq) Precedence Research, a leading strategic research firm, presents a comprehensive analysis of the AI-driven bioengineering market, covering protein design, AI-guided strain engineering, generative biology, and cloud bioengineering platforms. The market is accelerating as AI replaces years of wet-lab experiments with computational throughput measured in millions of protein sequences, billions of compounds screened, and tens of thousands of microbial strains designed annually.

Ottawa, Feb. 09, 2026 (GLOBE NEWSWIRE) -- According to data published by Precedence Research, the AI-driven bioengineering sector features companies like Ginkgo Bioworks ($478M revenue), Generate Biomedicines ($700M funding), and Recursion Pharmaceuticals ($261M revenue), designing millions of proteins and strains daily, screening over 15 billion compounds via AI, and training models on hundreds of millions of protein structures. Government programs in the USA, EU, UK, China, and Japan provide multi-billion-dollar funding, accelerating AI-enabled bioengineering innovation.

The AI-driven bioengineering market is transforming life sciences with high-throughput protein, strain, and compound design platforms, supported by hundreds of millions to billions in global funding, data published by Precedence Research.

Invest in Our Premium Strategic Solution:

Key Company Insights

Company Country Real Revenue / Funding HARD NUMBERS (Platform-Specific) Platform Focus
Ginkgo Bioworks USA $478.4M (2023) 124 active programs; 50,000+ strain designs/year; Foundry >100 bioreactors AI-driven strain engineering
Recursion Pharmaceuticals USA $261M (2023) >23 PB biological image data; 50M+ experiments/year AI biology + phenomics
Insilico Medicine USA / HK $400M+ funding 30+ AI-generated drug candidates; 10 in clinical stage Generative biology
Exscientia UK $300M+ revenue >20 AI-designed candidates; 4 in clinical trials AI-designed therapeutics
Deep Genomics Canada $180M funding AI models trained on millions of RNA splicing variants RNA engineering
Generate Biomedicines USA $700M funding Millions of protein sequences/day Generative protein design
Atomwise USA $174M funding Screened 15+ billion compounds via AI Structure-based AI
Schrödinger USA $219M revenue (2023) Physics-ML hybrid models; >2,000 enterprise customers Molecular simulation
Benchling USA $100M+ ARR 200k+ scientists; 1,200+ companies Cloud bioengineering OS
Zymergen USA $630M funding (pre-acquisition) AI-guided strain optimization; thousands of variants/run ML-guided materials bio
Arzeda USA $110M funding Enzyme yield improvements 5–10× Computational enzyme design
Absci USA $74M revenue (2023) End-to-end AI-to-wet-lab protein pipeline AI biologics
Owkin France / USA $304M funding Federated learning across 100+ hospitals AI + biomedical data
Valo Health USA $190M funding Human-centric AI platform; multi-omics scale AI bioengineering
Google DeepMind UK Alphabet funded AlphaFold trained on 200M+ proteins Protein structure prediction

Platform Throughput & Compute

Platform Real Throughput / Scale
Ginkgo Bioworks 50k+ strain designs/year
Recursion Pharmaceuticals 50M+ experiments/year
Generate Biomedicines Millions of protein designs/day
Atomwise 15B compounds screened
DeepMind AlphaFold 200M protein structures released
Benchling 200k+ active scientific users

Government & Public Sector Funding

Country Agency Program REAL FUNDING
USA DARPA Living Foundries $300M+
USA NIH AI-enabled biology grants $1.4B (FY2023)
USA DOE BioFoundry Network $580M cumulative
EU European Commission Horizon Europe AI + Bio €95.5B program
UK UKRI AI for Life Sciences £1B+ allocated
China MOST AI + Biotechnology ¥10B+ public funding
Japan METI Bio-Digital Transformation ¥100B+ strategy

Market Insights

  • High-Throughput AI Platforms: Companies design millions of proteins and microbial strains per day, screen billions of compounds, and model hundreds of millions of protein structures.
  • Acceleration of Discovery: AI reduces years of experimental iteration into days of compute, enabling rapid drug candidate identification and biomaterial optimization.
  • Government Investment: Hundreds of millions to billions in public funding worldwide drive platform access, research partnerships, and commercialization.
  • Revenue Models: Most revenue today stems from platform access, collaborations, and partnerships rather than end products.

How Precedence Research Can Help

Precedence Research delivers actionable insights and quantitative intelligence for AI-driven bioengineering:

  • Company Financial & Platform Data: Revenue, funding, AI throughput, and active program counts.
  • Government & Public Funding: DARPA, NIH, DOE, Horizon Europe, UKRI, METI, and MOST allocations.
  • Market Forecasting & Scenario Modeling: Platform adoption, AI throughput growth, and commercialization impact.
  • Strategic Reports: Tailored insights for investment, R&D prioritization, and partnership strategies.

Contact Us:
Email: ...
USA: +1 8044 419344 | APAC: +61 4859 81310 / +91 87933 22019 | Europe: +44 7383 092 044

Precedence Research – Transforming AI and Bioengineering Data into Strategic Decisions


MENAFN09022026004107003653ID1110714516



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Tags

Label

Comments

No comment

Category

Date
Search